Beaumont Asset Management L.L.C. Has $658,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Beaumont Asset Management L.L.C. lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,403 shares of the medical equipment provider’s stock after selling 1,163 shares during the quarter. Beaumont Asset Management L.L.C.’s holdings in Zimmer Biomet were worth $658,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. increased its holdings in Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the last quarter. Boston Partners increased its holdings in Zimmer Biomet by 29.2% in the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock valued at $302,366,000 after purchasing an additional 608,959 shares during the last quarter. Barclays PLC increased its holdings in Zimmer Biomet by 129.2% in the third quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider’s stock valued at $120,356,000 after purchasing an additional 604,652 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Zimmer Biomet in the third quarter valued at about $57,972,000. Finally, Jupiter Asset Management Ltd. bought a new stake in Zimmer Biomet in the third quarter valued at about $50,763,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $0.74 during mid-day trading on Tuesday, reaching $121.52. 742,692 shares of the company were exchanged, compared to its average volume of 1,460,520. The company has a fifty day simple moving average of $126.23 and a 200-day simple moving average of $119.37. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The firm has a market cap of $24.97 billion, a PE ratio of 24.70, a PEG ratio of 2.19 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the company earned $1.88 EPS. The company’s revenue was up 6.3% on a year-over-year basis. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent analyst reports. Raymond James increased their price target on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Citigroup increased their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Truist Financial increased their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Finally, Evercore ISI increased their price target on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.